Evaluate the safety and tolerability of FOR46 at escalating dose levels and administered intravenously (IV) every 21 days in relapsed/refractory multiple myeloma patients. And determine the maximum-tolerated dose and/or the recommended Phase 2 dose (RP2D) of FOR46 administered IV every 21 days in relapsed/refractory multiple myeloma patients.
University of Colorado Hospital
Tomer Mark, MD
Protocol Number: 18-2354
More information available at ClinicalTrials.gov: NCT03650491
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers